跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
anti-KRAS
首页
药物
anti-KRAS
anti-KRAS
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ANTI-KRAS-G12D T CELL RECEPTORS
EP 3494133 B1
申请人: US HEALTH
优先权: 2016
CN
EP
US
WO
15 件公开
ANTI-MUTATED KRAS T CELL RECEPTORS
EP 3223850 B1
申请人: US HEALTH
优先权: 2014
EP
US
WO
9 件公开
KRAS SPECIFIC ANTIBODIES AND USES THEREOF
EP 4143237 A1
申请人: GENENTECH INC
优先权: 2020
CN
EP
US
WO
5 件公开
CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS
EP 3082957 B1
申请人: BIOMED VALLEY DISCOVERIES INC
优先权: 2013
EP
US
WO
5 件公开
SOLUBLE TORS AND FUSIONS TO ANTI-CD3 RECOGNISING KRAS G12D FOR THE TREATMENT OF CANCER
EP 4146257 A1
申请人: IMMUNOCORE LTD
优先权: 2020
CN
EP
US
WO
4 件公开
ANTIBODY TARGETING INTRACELLULAR TUMOR-INDUCING PROTEIN, OR FUSION PROTEIN OF SINGLE STRAND VARIABLE FRAGMENT THEREOF AND CANCER-CELL-PENETRATING PEPTIDE, AND USE THEREOF
EP 4198058 A4
申请人: NIBEC CO LTD
优先权: 2020
CN
EP
US
WO
4 件公开
PHARMACEUTICAL COMPOSITION, USE THEREOF, AND METHOD FOR TREATING CANCER
EP 4506004 A4
申请人: GENFLEET THERAPEUTICS SHANGHAI INC
优先权: 2022
CN
EP
US
WO
4 件公开
COMPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT FOR ENHANCING ANTICANCER EFFECT OF KRAS G12C GENETIC MUTATION THERAPEUTIC AGENT
EP 4523688 A4
申请人: KOREA INST RADIOLOGICAL & MEDICAL SCIENCES
优先权: 2022
CN
EP
US
WO
4 件公开
COMPOUNDS WITH ANTI-KRAS MUTANT TUMOR ACTIVITY
EP 4596551 A1
申请人: TRASVEDA LTD
优先权: 2022
CN
EP
US
WO
4 件公开
SCREENING AND ANTITUMOR USE OF KRAS MUTATION SPECIFIC T CELL RECEPTOR
EP 4223771 A4
申请人: INST MICROBIOLOGY CAS
优先权: 2020
CN
EP
US
4 件公开
第 1 / 10 页
上一页
下一页
药物
反馈